BASELGA, J. Phase I safty, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol. 2002, 20, 4292-4302
DOORN, RV. Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor. Br J Dermatol. 2002, 147, 598-601
NANNEY, LB. Comparison of epidermal growth factor binding and receptor distribution in normal human epidermal appendages. J Invest Dermatol. 1984, 83, 385-393
BUNSAM, KJ. Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol. 2001, 144, 1169-1186